Italian gene therapy player draws new investor from China for its answer to CAR-T relapses
So you’ve been treated with one of the new-age cancer therapies. What do you do if there’s a relapse and the tumors returns?
Genenta Science launched four years ago out of Milan in part to answer that question, and today they received $14.4 million in round three funding that will propel their unique gene therapy through Phase I/II trials for multiple myeloma and glioblastoma. Backed now by money from the Chinese firm Qianzhan Investment Management and Fidim, the former owner of the biopharmaceutical Rottapharm, the company is also exploring ways of delivering gene therapy to solid tumors that have been harder to reach.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.